NCT05768217 Community Resiliency Collective Efficacy Intervention
| NCT ID | NCT05768217 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Violence, Physical |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,600 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4,600 participants in total. It began in 2024-06-24 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate, via a cluster-randomized controlled trial, the effectiveness of a community-centered intervention that promotes thriving and resiliency to reduce community violence.
Eligibility Criteria
Inclusion Criteria: * youth age 13 years old and up (all genders) * adults 18 years and older (all genders) * reside in neighborhoods selected to participate in the study Exclusion Criteria: * individuals younger than 13 years old * individuals residing outside of participating neighborhoods
Contact & Investigator
Alison Culyba, MD, PhD, MPH
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT05768217 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, studying Violence, Physical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05768217 currently recruiting?
Yes, NCT05768217 is actively recruiting participants. Contact the research team at clg166@pitt.edu for enrollment information.
Where is the NCT05768217 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT05768217 clinical trial?
NCT05768217 is sponsored by University of Pittsburgh. The principal investigator is Alison Culyba, MD, PhD, MPH at University of Pittsburgh. The trial plans to enroll 4,600 participants.